## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.2% below STRENGTH zone (4.0-10.0%); PEG 1.89 fails VALUE criteria (<1.0); RSI 71 overbought. Stock is in no-man's land without clear edge. Caution: declining volume (53% of avg), momentum weakening (-7.4% MRS), overbought RSI (71).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($199.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. CAH SEC Filings - Cardinal Health Inc 10-K, 10-Q, 8-K Forms**
- Source: Stock Titan | 20251201T182131 | Neutral | Relevance: 98%
- This page provides an overview of Cardinal Health (CAH) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries and real-time alerts for insider transactions. Recent filings detail performance-based share awards to key executives, a Form S-3 shelf prospectus, and fiscal year 2025 financial results showing increased operating earnings despite a revenue dip. The company also announced an acquisition and year-end results reporting.

**2. Is There Opportunity in Henry Schein After 18% Rally and Digital Dentistry Expansion?**
- Source: Simply Wall Street | 20251201T045231 | Neutral | Relevance: 60%
- Henry Schein's stock recently rallied 18%, sparking debate on its future growth and risk. The company shows a strong valuation score of 5 out of 6 according to Simply Wall St's valuation checks, and a Discounted Cash Flow (DCF) analysis suggests it is significantly undervalued by 57.2%. Its Price-to-Earnings (PE) ratio is currently 22.45x, suggesting it is about fairly valued when compared to its tailored "Fair Ratio" of 24.99x.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.4% 5d) with bearish MACD, trend may be turning.
2. Overbought RSI (71) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.89 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.1B |
| Beta | 0.64 |
| 52W Range | $114.60 - $214.93 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.89 |
| Forward P/E | 18.8 |
| Current P/E | 21.2 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 7.6% to 0.2% (-7.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.8pp (needs >4.0% for momentum thesis). MRS_5 (-2.3%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.15), momentum weakening. RSI overbought at 71, risk of mean reversion. Volume at 53% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.20% (CS: 54) | Neutral |
| RSI_14 | 71.3 | Overbought |
| MACD Histogram | -1.15 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.172x | Above |
| vs SMA200 | 1.346x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $208.00
- **Stop Loss:** $199.40 (4.1% risk)
- **Target:** $216.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 87
- **Position Value:** $18,096.00
- **Portfolio %:** 18.10%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*